Whole-Brain Tumor Burden Metrics with Inflammatory and Molecular Markers to Predict Postoperative Neurocognitive Decline in Glioma

NCT06885333 | Completed DMC

• 1 other identifier: 2023745
• Study Type: observational
• Target: 192
• Locations: 0 countries
• Sites: N/A

Brief Summary

Although surgical resection improves overall survival in patients with diffuse Low-grade gliomas (DLGG), it can also result in deterioration of neurocognitive function, which are poorly understood and lack effective predictive models. This study aims to develop a model using whole-brain tumor burden metrics, inflammatory and molecular markers for predicting high risk of neurocognitive decline (ND) postoperatively. The study involved 192 patients with left frontal DLGG. MRI data were analyzed to derive whole-brain tumor burden metrics, including tumor radiomics, whole-brain cortical thickness, myelin content, and network characteristics. postoperative inflammatory and molecular markers were collected. Postoperative follow-up neurocognitive function was assessed using the Montreal Cognitive Assessment at 3 months and 1 year. Machine learning models were constructed using Pycaret.

Conditions

Glioma; Glioma : Oligodendroglioma or Astrocytoma

Outcome Measures

Primary Outcomes (1)

• neurocognitive function was assessed using the Montreal Cognitive Assessment

  p neurocognitive function was assessed using the Montreal Cognitive Assessment

  3 month

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

192 glioma patients

You may qualify if:

• Histopathologically proven DLGG based on 2021 WHO criteria
• Age ≥ 18 years,
• Karnofsky Performance Status ≥ 70%,
• Tumor involved unilateral left frontal lobe and did not reach the central sulcus.

You may not qualify if:

• With previous treatment before image acquisition,
• Presenting cognitive impairment pre-operatively based on The Montreal Cognitive Assessment (MoCA)
• Survival of less than 3 months post-surgery
• Lack of compliance with neurocognitive assessments in 3-month and 1-year after surgery

Sponsors & Collaborators

• West China Hospital: lead

MeSH Terms

Conditions

Glioma; Astrocytoma

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: doctor of department of radiology, Principal Investigator, Clinical Professor

Study Record Dates

• First Submitted: March 11, 2025
• First Posted: March 20, 2025
• Study Start: May 1, 2016
• Primary Completion: September 1, 2024
• Study Completion: December 1, 2024
• Last Updated: March 20, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will share